106 related articles for article (PubMed ID: 27432558)
41. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
42. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
43. Selective activity of BS-RNase against anaplastic thyroid cancer.
Kotchetkov R; Cinatl J; Krivtchik AA; Vogel JU; Matousek J; Pouckova P; Kornhuber B; Schwabe D; Cinatl J
Anticancer Res; 2001; 21(2A):1035-42. PubMed ID: 11396137
[TBL] [Abstract][Full Text] [Related]
44. Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice.
Quidville V; Segond N; Tebbi A; Cohen R; Jullienne A; Lepoivre M; Lausson S
Thyroid; 2009 Jun; 19(6):613-21. PubMed ID: 19281427
[TBL] [Abstract][Full Text] [Related]
45. Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways.
Yang Q; Ji M; Guan H; Shi B; Hou P
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1909-17. PubMed ID: 24106286
[TBL] [Abstract][Full Text] [Related]
46. Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
Pucciarelli D; Lengger N; Takacova M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
Int J Oncol; 2015 Jul; 47(1):81-90. PubMed ID: 25997619
[TBL] [Abstract][Full Text] [Related]
47. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
48. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
49. Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells.
Pilli T; Cantara S; Marzocchi C; Pacini F; Prabhakar BS; Castagna MG
Endocrine; 2020 Jan; 67(1):117-123. PubMed ID: 31377969
[TBL] [Abstract][Full Text] [Related]
50. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
51. The novel indole compound SK228 induces apoptosis and FAK/Paxillin disruption in tumor cell lines and inhibits growth of tumor graft in the nude mouse.
Huang SM; Hsu PC; Chen MY; Li WS; More SV; Lu KT; Wang YC
Int J Cancer; 2012 Aug; 131(3):722-32. PubMed ID: 22015944
[TBL] [Abstract][Full Text] [Related]
52. Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Lee WR; Shen SC; Shih YH; Chou CL; Tseng JT; Chin SY; Liu KH; Chen YC; Jiang MC
J Transl Med; 2015 Jun; 13():191. PubMed ID: 26070816
[TBL] [Abstract][Full Text] [Related]
53. Epinephrine Stimulates Cell Proliferation and Induces Chemoresistance in Myeloma Cells through the β-Adrenoreceptor in vitro.
Liu Y; Yu X; Zhuang J
Acta Haematol; 2017; 138(2):103-110. PubMed ID: 28848082
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
[TBL] [Abstract][Full Text] [Related]
55. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
Gong JH; Liu XJ; Li Y; Zhen YS
Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
[TBL] [Abstract][Full Text] [Related]
56. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY
Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383
[TBL] [Abstract][Full Text] [Related]
57. Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy.
Hedrick E; Lee SO; Doddapaneni R; Singh M; Safe S
Endocr Relat Cancer; 2015 Oct; 22(5):831-40. PubMed ID: 26229035
[TBL] [Abstract][Full Text] [Related]
58. Propranolol suppresses gastric cancer cell growth by regulating proliferation and apoptosis.
Koh M; Takahashi T; Kurokawa Y; Kobayashi T; Saito T; Ishida T; Serada S; Fujimoto M; Naka T; Wada N; Yamashita K; Tanaka K; Miyazaki Y; Makino T; Nakajima K; Yamasaki M; Eguchi H; Doki Y
Gastric Cancer; 2021 Sep; 24(5):1037-1049. PubMed ID: 33782804
[TBL] [Abstract][Full Text] [Related]
59. Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.
Stiles JM; Amaya C; Rains S; Diaz D; Pham R; Battiste J; Modiano JF; Kokta V; Boucheron LE; Mitchell DC; Bryan BA
PLoS One; 2013; 8(3):e60021. PubMed ID: 23555867
[TBL] [Abstract][Full Text] [Related]
60. Dissecting the role of cell signaling versus CD8
Li W; Wan J; Chen C; Zhou C; Liao P; Hu Q; Hu J; Wang Y; Zhang Y; Peng C; Huang Y; Huang W; Zhang W; Mcleod HL; He Y
J Mol Med (Berl); 2022 Sep; 100(9):1299-1306. PubMed ID: 35895125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]